Position:Emeritus Director
PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240
Email:rury.holman@dtu.ox.ac.uk
ORCID ID0000-0002-1256-874X
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Manuscript
Serial Assessment of NT-proBNP and High-Sensitivity Cardiac Troponin with Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: Insights from EXSCEL
Veraprapas Kittipibul et al.
Am Heart J. 2026;299:107475
Manuscript
To cluster or not to cluster? A comparison of approaches to targeting type 2 diabetes glucose lowering therapy in the TRIMASTER Crossover Trial
Güdemann LM et al.
Diabetes Care 2026
Manuscript
Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study
Katherine G Young et al.
Diabetes Care 2026;49:1115-1123
Manuscript
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum
Oliver Schnell et al.
Cardiovasc Diabetol. 2026;25:142
Manuscript
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists
Mahesh M Umapathysivam et al.
Genome Med. 2026
Manuscript
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease
Abhinav Sharma et al.
JACC Adv. 2026;5:102598